LUNG ADENOCARCINOMA
Clinical trials for LUNG ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LUNG ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat tumors in early trial
Disease control TerminatedThis study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental cancer pill targets genetic weakness in Hard-to-Treat tumors
Disease control TerminatedThis study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Lung cancer gene study halted early
Knowledge-focused TerminatedThis study looked at the genetics of people with multiple lung tumors (multifocal lung adenocarcinoma). Researchers collected tissue and blood samples from 100 participants during surgery to analyze their DNA. The goal was to see if genetic information could help guide treatment …
Matched conditions: LUNG ADENOCARCINOMA
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC